Repeated CBD Administration and Cannabis Outcomes

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Cannabis, Abuse Liability, Experimental Pain in Healthy Human Participants

In brief

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Key facts

Study ID

NCT07434895

Run by

Hannah Harris

People needed

23

Starts

2026-08-01

Expected to finish

2029-12-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• English-speaking, literate adults,
• Male or female,
• Between the ages of 18-55,
• Body Mass Index from 18.5-32.0 kg/m2,
• Not currently seeking treatment for cannabis or drug use,
• Able to provide written informed consent and perform all study procedures,
• If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
• Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
• Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.

You may not qualify if…

• Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
• Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),
• Current or past history of major psychiatric disorder that would limit ability to participate in the study,
• Use of cannabis exclusively for medical reasons (no recreational use reported),
• Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
• Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
• Clinically significant abnormal ECG (as determined by study physician/cardiologist),
• Clinically significant abnormal laboratory findings,
• History of seizure disorder,
• Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
• Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).

Where it is running

• University of Kentucky — Lexington, Kentucky, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.